רווח תפעולי EBITDA 111, Inc (YI)

Is it worth investing in 111, Inc. (YI), given the pressure from Chinese regulators and low retail margins? The actual EBITDA provides the answer: the indicator stands at 0.00. 111, Inc. (YI) is developing digital medicine through alliances with clinics, optimizing B2B supplies. The business is currently executing an operational pivot, prioritizing net profit over simple sales volume growth.

For 111, Inc., the efficiency of the vertical integration between e-health services and the pharmacy network is reflected in the volume of cash generated by the core business before depreciation and interest. This metric measures the platform's actual ability to convert patient flow into cash; therefore, current operating cash flow serves as a leading indicator of the scaling model's sustainability within the PRC market.